ArticleBioinformation2025
Investigating the efficacy of non-invasive vagus nerve stimulation in treating drug-resistant epilepsy.
Article in Bioinformation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Non-invasive neuromodulation for drug-resistant epilepsy: a contemporary structured review of mechanisms, clinical evidence and future directions.Frontiers in neurology · 2026Review
- Left vagus nerve magnetic stimulation facilitates nasogastric tube removal in post-stroke patients with dysphagia: a prospective observational cohort study.Frontiers in neurologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Drug-resistant epilepsy (DRE) affects approximately 30% of individuals with epilepsy who do not respond to antiepileptic drugs. This randomized controlled trial evaluated the efficacy of non-invasive vagus nerve stimulation (nVNS) in 120 DRE patients. Over 12 weeks, the intervention group showed a 45% reduction in seizures and a 30% improvement in quality of life, both statistically significant. Minor side effects included headaches and neck discomfort. nVNS appears to be a safe and effective adjunctive therapy for managing DRE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.